Jorge Plutzky

Nov 18, 2024 | jacc.org | Subodh Verma |Scott Emerson |Jorge Plutzky |Steven Kahn

Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and ObesitySign in, Subscribe, or Pay to View

May 29, 2024 | medscape.com | Jorge Plutzky |Brian McMahon

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. This transcript has been edited for clarity. Jorge Plutzky, MD: Hi. I'm Dr Jorge Plutzky, director of preventive cardiology at the Brigham and Women's Hospital, and in that setting I direct our lipid clinic. I'm pleased to be here today to talk about how we communicate about cholesterol.

May 13, 2024 | nature.com | Ildiko Lingvay |Eric Barros |Helen M. Colhoun |Cintia Cercato |A. Michael Lincoff |Jorge Plutzky

AbstractIn the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI).